# US 2015/0105362 A1 · Synthesis of estetrol via estrone derived steroids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105362 A1
- Document ID: US20150105362A1
- Status: Published application
- Kind: A1
- Application number: 14/578,137
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2002-11-08
- Assignees: Pantarhei Bioscience B.V.
- Applicants: Pantarhei Bioscience B.V.
- Inventors: Mark Theodoor Verhaar; Thomas Koch; Erwin Gerardus Jacobus Warmerdam
- Web page: https://patentgrep.com/patent/US20150105362A1

## CPC

- C07J 1/007: {the substituent being an OH group free esterified or etherified}
- C07J 1/0059: {substituted in position 17 by a keto group}
- C07J 1/0066: {substituted in position 17 beta not substituted in position 17 alfa}
- C07J 21/00: Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07J: STEROIDS (seco-steroids C07C)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C1-C5 alkyl group, preferably a methyl group, or a C7-C12 benzylic group, preferably a benzyl group. This process is particularly suitable to industry.

## Claims

### Claim 1

A process for the preparation of estra-1,3,5(10)-trien-3,15α,16α,17β-tetraol, comprising:
(a) converting estrone into 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is a protecting group;
(b) reducing the 17-keto group of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one to 3-A-oxy-estra-1,3,5(10),15-tetraen-17β-ol;
(c) protecting the 17-OH group of 3-A-oxy-estra-1,3,5(10),15-tetraen-17β-ol to 3-A-oxy-17-C-oxy-estra-1,3,5(10),15-tetraene, wherein C is a protecting group;
(d) oxidizing the carbon-carbon double bond of ring D of 3-A-oxy-17-C-oxy-estra-1,3,5(10),15-tetraene to protected estetrol; and
(e) removing the protecting groups, wherein preferably protecting group A is removed first to form 17-OC protected estetrol and subsequently protecting group C is removed to form estetrol;
wherein the protecting group A is selected from an C1-C5 alkyl group or a C7-C12 benzylic group and the protecting group C is selected from monofunctional aliphatic hydroxyl protecting groups.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the protecting group is a C7-C12 benzylic group, or a benzyl group.

### Claim 3 (depends on 1)

The process according to claim 1, wherein the monofunctional aliphatic hydroxyl protecting group is acetyl.

### Claim 4 (depends on 1)

The process according to claim 1, wherein the reduction of the carbonyl group is carried out using a reducing agent selected from the group of metal hydride compounds.

### Claim 5 (depends on 4)

The process according to claim 4, wherein the metal hydride compound is selected from the group consisting of LiAlH4, NaBH4, NaBH(OAc)3, ZnBH4, and NaBH4/CeCl3.

### Claim 6 (depends on 5)

The process according to claim 5, wherein the metal hydride compound is NaBH4 in combination with CeCl3 hydrate.

### Claim 7 (depends on 1)

The process according to claim 1, wherein the oxidation of the carbon-carbon double bond in ring D is carried out with an oxidizing agent comprising osmium tetroxide.

### Claim 8 (depends on 7)

The process according to claim 7, wherein the oxidizing agent is osmium tetroxide immobilized on PVP (OsO4-PVP).

### Claim 9 (depends on 1)

The process according to claim 1, wherein the oxidation of the carbon-carbon double bond in ring D is carried out with a catalytic amount of OsO4-PVP.

### Claim 10 (depends on 9)

The process according to claim 9, wherein OsO4-PVP is used in combination with a co-oxidant.

### Claim 11 (depends on 10)

The process according to claim 10, wherein the co-oxidant is selected from the group consisting of trimethylamine-N-oxide, N-methyl morpholine-N-oxide or hydrogen peroxide.

### Claim 12 (depends on 11)

The process according to claim 11, wherein the co-oxidant is trimethylamine-N-oxide.

### Claim 13 (depends on 1)

The process according to claim 1, wherein the protective C7-C12 benzylic group is removed by catalytic hydrogenation conditions.

### Claim 14 (depends on 13)

The process according to claim 13, wherein the catalytic hydrogenation conditions comprise a hydrogenation reaction using Pd on activated carbon under a hydrogen atmosphere.

### Claim 15 (depends on 1)

The process according to claim 1, wherein the protective C1-C5 alkyl group is removed by using BBr3.

### Claim 16

A process the preparation of 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, comprising:
(a) converting the 17-keto group of estron into a protected keto group to form 17-D-estra-1,3,5(10)-trien-3-ol;
(b) converting the 3-OH group of 17-D-estra-1,3,5(10)-trien-3-ol into a 3-AO group to form 3-A-oxy-17-D-estra-1,3,5(10)-trien-17-one;
(c) halogenating C16 of 3-A-oxy-17-D-estra-1,3,5(10)-triene to form 3-A-oxy-16-X-17-D-estra-1,3,5(10)-triene wherein X is a halogen atom selected from the group chloride, bromide and iodide;
(d) dehalogenating 3-A-oxy-16-X-17-D-estra-1,3,5(10)-triene to 3-A-oxy-17-D-estra-1,3,5(10),15-tetraene; and
(e) deprotecting the protected keto group of 3-A-oxy-17-D-estra-1,3,5(10),15-tetraene to form 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one;
wherein A is selected from an C1-C5 alkyl group or a C7-C12 benzylic group, and wherein D is ethylene dioxy.

### Claim 17 (depends on 16)

The process according to claim 16, wherein the protected keto group D is formed by converting the 17-keto group with ethylene glycol.

### Claim 18 (depends on 16)

The process according to claim 16, wherein step (e) is carried out in the presence of a component selected from the group consisting of p-toluenesulfonic acid, pyridinium p-toluenesulfonate, and pyridinium chloride.

### Claim 19 (depends on 16)

The process according to claim 16, wherein step (e) is carried out in the presence of p-toluenesulfonic acid.

### Claim 20 (depends on 1)

A pharmaceutical composition, comprising a carrier and a product obtainable by the method of claim 1.

### Claim 21 (depends on 20)

A method of hormone replacement therapy, treating vaginal dryness, contraception, enhancing libido, treating skin, promoting wound healing or of treating or preventing an autoimmune disease, breast tumours and colorectal tumours, comprising administering to a subject in need thereof the pharmaceutical composition of claim 20.
